9.18
+6.62%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Compass Pathways
From its filings with the US Securities and Exchange Commission
Compass Pathways is based in Chesire, United Kingdom and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker CMPS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $287.9m. At that date it held total assets of $210.3m and shareholders' equity of −$52.8m.
We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 psilocybin treatment, potentially a first in class treatment. COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.
We believe that our COMP360 psilocybin treatment could offer a new approach to treatment of serious mental health conditions, including treatment-resistant depression, or TRD, which is a subset of major depressive disorder, or MDD, post-traumatic stress disorder, or PTSD, and potentially many other serious mental health conditions.
Our initial focus is on TRD, comprising patients who are inadequately served by current treatment options. In 2018, we received Breakthrough Therapy designation from the U.S. Food and Drug Administration, or the FDA, for COMP360 for the treatment of TRD. In November 2021, we announced positive top-line results from our Phase 2b clinical trial evaluating COMP360 for the treatment of TRD. On November 3, 2022, The New England Journal of Medicine published the positive results from our Phase 2b trial.
Quoted from its 10-K, filed 24 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Sept 2020
- Employees
- 156
- Website
- compasspathways.com ↗
- Head office
- 3RD FLOOR, 1 ASHLEY ROAD, CHESIRE, X0, WA14 2DT
- Incorporated in
- X0
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Gino SantiniNon-Executive Independent Chairman of the Board$410,440
- Mr. Kabir NathChief Executive Officer, Executive Director, since 2022$4.3m
- Ms. Teri LoxamChief Financial Officer$2.3m
- Dr. Guy GoodwinChief Medical Officer$1.5m
- Mr. Justin GoverDirector
- Dr. Jeffrey JonasDirector
- Dr. Annalisa JenkinsIndependent Director$290,276
- Ms. Daphne KarydasIndependent Director$277,540
- Mr. Thomas LonngrenIndependent Director$271,788
- Dr. Linda McgoldrickIndependent Director$277,790
- Dr. Robert McQuadeIndependent Director$282,790
- Mr. David NortonIndependent Director$411,562
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Compass Pathways PLC has several strengths that contribute to its success in the market. Firstly, the company is backed by significant funding, allowing it to invest in research and development and establish itself as a key player in the emerging field of mental health treatment. Secondly, Compass Pathways has a strong network of partnerships and collaborations with leading academic institutions and healthcare organizations, enabling access to valuable expertise and resources. Lastly, the company has patented technologies and intellectual property, giving it a competitive edge in the development and commercialization of innovative therapies.
Weaknesses
- Despite its strengths, Compass Pathways PLC also faces certain weaknesses that could potentially hinder its growth. One of the major challenges is the high cost associated with the research and development of novel treatments, which may impact the company's profitability and ability to bring products to market in a timely manner. Additionally, as a relatively young company, Compass Pathways has limited brand recognition and market presence, which could pose obstacles in gaining traction and competing with established players in the industry.
Opportunities
- The market offers numerous opportunities for Compass Pathways PLC to capitalize on. The growing awareness and acceptance of psychedelic-assisted therapies present a favorable environment for the company to position itself as a leader in this therapeutic field. Furthermore, the increasing prevalence of mental health disorders globally creates a significant demand for effective treatments, offering a vast market for Compass Pathways' innovative solutions. Moreover, strategic partnerships and collaborations with pharmaceutical companies and healthcare providers can help accelerate the development, commercialization, and distribution of the company's therapies.
Threats
- Compass Pathways PLC faces several threats that could impact its business operations and market position. One prominent threat is the regulatory landscape and the potential for stringent regulations surrounding psychedelic-assisted therapies, which could limit market access and increase compliance costs. Additionally, competition within the mental health treatment industry is intensifying, and new entrants or existing players developing alternative therapies could erode Compass Pathways' market share. Moreover, there is a risk of unforeseen adverse events or negative public perception related to psychedelic treatments, which may lead to reputational damage and skepticism among key stakeholders.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.